Skip To Main Content
Simbarashe Takuva on Muck Rack

Simbarashe Takuva

As seen in: PLOS Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Simbarashe

Contact Simbarashe, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial

|
By Ishen Seocharan, Simbarashe Takuva, Azwidhwi Takalani
| PLOS Medicine Verified
Serious adverse events A total of 138 SAEs (excluding deaths) were reported by 136 participants (median age 42 years, IQR 35–51), with 113 (81.9%) reported by women and 25 (18.1%) by men. Most SAEs (115; 82.7%) occurred within 28 days of vaccination, with a median time to onset of 5 days (IQR 1–17) for all SAEs, and a median time of onset of 1 day (IQR 0–9) for SAEs occurring with 28 days of vaccination.
Open in Who Shared Issue with article?
See all 1 articles